Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267601 | 0.87 | HTT (0.47) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL9462404 | 0.82 | SOD1 (0.49) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL29707985 | 0.80 | SOD1 (0.47) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL152556 | 0.80 | SOD1 (0.47) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL2633667 | 0.80 | SOD1 (0.47) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL10788348 | 0.78 | HSD17B1 (0.47) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL6038490 | 0.78 | CA2 (0.56) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| SCHEMBL27781093 | 0.77 | HSD17B1 (0.46) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| Hydrochloric Acid SCHEMBL27591360 | 0.77 | HSD17B1 (0.46) | SOD1HSD17B1HSD17B2KMT2ACA12 | |
| Water SCHEMBL29026586 | 0.75 | CD44 (0.58) | SOD1GLATSHRCD44LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | SOD1 4528/4885HSD17B1 1352/4885HSD17B2 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.